The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy
Frontiers in Public Health · 03.07.2025 · 13
DOI: 10.3389/fpubh.2025.1604331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 03.07.2025. Verfasst von Vieri Lastrucci und 15 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology Unit, Meyer Children's Hospital IRCCS, Florence, Italy. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Antiviral Agents, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Respiratory Syncytial Virus (RSV) is the leading cause of hospitalizations in infants. The approval of nirsevimab, a long-acting monoclonal antibody, has extended the potential for RSV prophylaxis to all infants. This study assesses the cost–benefit of various Nirsevimab prophylaxis strategies for infants during their first RSV season in preventing RSV-associated hospitalization in the Tuscany region, Italy.
Methods
The analysis was conducted from the perspective of the healthcare payor. Real-world data from the Tuscany birth cohort ( N = 21,017) experiencing their first RSV season in the 2023/2024 season were used to calculate the net benefit and benefit cost ratio (BCR) of three possible nirsevimab prophylaxis strategies compared with prophylaxis practices at the time of the study, which includes the use of palivizumab in eligible infants. RSV-associated hospitalizations and severe hospitalizations were considered as health outcomes. Sensitivity analyses were performed to identify influential variables.
Results
Under prophylaxis practices at the time of the study, there were a total of 663 hospitalizations associated with RSV, including 102 severe cases, representing €5,247,645 in costs. An extended prophylaxis strategy with nirsevimab, including all infants born both before and during the RSV season, resulted in the highest number of hospitalizations avoided (378), with a BCR close to break-even (0.96). A seasonal-only strategy targeting infants born during the season prevented the fewest hospitalizations (252), showing a positive BCR of 1.15. Finally, a seasonal strategy with targeted catch-up, including also preterm infants born before the season, yielded the highest cost–benefit ratio (1.56), preventing 270 hospitalizations.
Conclusion
Universal prophylaxis strategies with nirsevimab, targeting all infants during their first RSV epidemic season, substantially reduce hospitalization burdens without increasing economic pressure on the healthcare system. Although alternative strategies are more cost-effective, they prevent fewer hospitalizations, emphasizing the public health value of broader prophylaxis approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Epidemiology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Epidemiologic Observatory, Regional Healthcare Agency of Tuscany, Florence, Italy.
- Neonatal Intensive Care Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
- Pediatrics and Neonatology Unit, Santo Stefano Hospital, USL Toscana Centro, Prato, Italy.
- Department of Neurofarba, University of Florence, Florence, Italy.
- Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Zitieren
APA
Lastrucci, V., Pacifici, M., Alderotti, G., Puglia, M., Berti, E., Barbati, F., Lodi, L., Boscia, S., Nieddu, F., Indolfi, G., Peroni, D., Martini, M., Azzari, C., Voller, F., Moriondo, M., & Ricci, S. (2025). The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy. Frontiers in Public Health, 13. https://doi.org/10.3389/fpubh.2025.1604331
Vancouver
Lastrucci V, Pacifici M, Alderotti G, Puglia M, Berti E, Barbati F, et al. The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy. Frontiers in Public Health. 2025;13. doi:10.3389/fpubh.2025.1604331
BibTeX
@article{Lastrucci2025,
author = {Lastrucci, Vieri and Pacifici, Martina and Alderotti, Giorgia and Puglia, Monia and Berti, Elettra and Barbati, Federica and Lodi, Lorenzo and Boscia, Silvia and Nieddu, Francesco and Indolfi, Giuseppe and Peroni, Diego and Martini, Marco and Azzari, Chiara and Voller, Fabio and Moriondo, Maria and Ricci, Silvia},
title = {The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy},
journal = {Frontiers in Public Health},
year = {2025},
volume = {13},
doi = {10.3389/fpubh.2025.1604331}
}
EUVIMED